We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Chagas Disease Unfamiliar to Many U.S. Physicians

By LabMedica International staff writers
Posted on 26 Oct 2010
Chagas disease manifests both as an acute or chronic disease, caused by the parasitic protozoa Trypanosoma cruzi and should no longer be thought of as exotic. More...


The diagnosis of Chagas disease can be made by observation of the parasite in a blood smear by microscopic examination. A thick and thin blood smear are made and stained for visualization of parasites. However, a blood smear works well only in the acute phase of infection when parasites are seen circulating in blood. For screening blood donated for transfusion, antibody detection tests are available.

The disease is spread by infected insects called triatomine bugs and is only transmitted on the American continents. Infection can also occur through blood transfusions, ingestion of contaminated food or drink, organ transplants, and from an infected mother to her unborn child. For obstetricians and gynecologists in the U.S., increased awareness around Chagas disease is important because many newly diagnosed patients are identified among blood donors who are women of childbearing age and at risk of transmitting the infection to their newborns. Although congenital Chagas disease is relatively rare in the US, the estimated 300 annual cases are similar to other rare diseases for which all newborns in the U.S. are routinely screened at birth.

A survey published in the October 2010 issue of the American Journal of Tropical Medicine and Hygiene, revealed that knowledge and understanding of this condition is low among obstetrician-gynecologists. The survey results found that only 3% of the physicians surveyed considered their knowledge about Chagas disease excellent or good compared to a large majority (88%) who described their knowledge as limited or very limited; almost 10% of those surveyed reported never having heard of the disease at all. One-third of survey respondents did not know what causes the disease, and only 58% were able to identify it correctly as a parasitic infection.

Jennifer R. Verani, M.D., from the Center for Disease Control and Prevention (CDC; Atlanta, GA; USA), said, "The good news about the survey results is that the majority of physicians respondents were not misinformed, they just did not have information about Chagas disease.” Edward T. Ryan, M.D., President of American Society of Tropical Medicine and Hygiene, added, "There are potentially 100,000 women living in the U.S. who are at risk of infecting their unborn babies. We need to educate obstetricians, family practitioners, nurse midwives, and pediatricians about Chagas, especially those who care for families from Latin America."

If left untreated, Chagas disease can cause complications such as cardiomyopathy, heart disease, heart failure, enlargement of the colon, enlargement of the esophagus and malnutrition. An estimated 20% to 30% of patients will develop the cardiovascular/digestive complications, decades after the initial infection.

Related Links:

CDC


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.